<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158856</url>
  </required_header>
  <id_info>
    <org_study_id>SHERO</org_study_id>
    <nct_id>NCT04158856</nct_id>
  </id_info>
  <brief_title>Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer</brief_title>
  <acronym>SHERO</acronym>
  <official_title>Adjuvant Dual Anti-HER2 Therapy in Patients With Tumors &lt; 8mm, Node-negative, HER2-positive Breast Cancer :a Single-group Arm, Open-label, Prospective, Phase 2 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>xuexin he</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial aims to study the efficacy and safety of adjuvant Pyrotinib plus
      trastuzumab in patients with tumors &lt;8mm, node-negative, HER2-positive breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2030</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>stimated percentage of patients alive and disease-free at 5 years from randomization or censored at date of last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast Cancer Specific Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where breast cancer specific survival is defined as the time from randomization to death from breast cancer relapse; or censored at date last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Estimated percentage of patients alive and disease-free at 5 years from randomization, where overall survival is defined as the time from randomization to death from any cause; or censored at date last known alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Incidence and severity of adverse events as assessed by NCI CTCAE V5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of LVEF after treatment</measure>
    <time_frame>up to 3 months</time_frame>
    <description>The change of LVEF after 3 months treatment compared to the baseline LVEF</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HER2-positive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>adjuvant Pyrotinib plus Trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>400mg po every day</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Pyrotinib Maleate Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg every 21 days</description>
    <arm_group_label>Experimental Arm</arm_group_label>
    <other_name>Herceptin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged 18-70 years old

          2. Have finished radical operation

          3. Histologically confirmed invasive ductal carcinoma (IDCA)

          4. According to AJCC ,pT&lt;8mm, pN0, no evidence for metastasis

          5. Operation specimens are available for ER, progesterone receptor (PR) and HER2
             detection, patients should be HER2 positive tumor (IHC staining of 3+ [uniform,
             intense membrane staining of &gt;30% of invasive tumor cells], or a FISH result of .6
             HER2 gene copies per nucleus or a FISH ratio [HER2 gene signals to chromosome 17
             signals] of &gt;2.2), nuclear grade 3.

          6. Should have tumor tissue available and sufficient for multi-spots sampling.

          7. It has been &lt;84 days since the date of definitive surgery, and there is adequate wound
             healing as determined by the Treating Physician.

          8. Has Eastern Cooperative Oncology Group (ECOG) Performance Score 0-1, expected survival
             time ＞ 12 months

          9. Cardiac function had to be within normal limits (left ventricular ejection fraction
             [LVEF] ≥50%), as established by multiple gated acquisition scan or echocardiography.

         10. Adequate bone marrow function, adequate liver and renal function, and adequate
             coagulation function.

         11. Women with potential child-bearing must have a negative pregnancy test (urine or
             serum) within 7 days of drug administration and agree to use an acceptable and
             effective method of contraception to avoid pregnancy during the study.

         12. Written informed consent according to the local ethics committee requirements.

        Exclusion Criteria:

          1. pT≥8mm or node positive

          2. Metastatic breast cancer

          3. Any prior systemic or loco-regional treatment of breast cancer, including chemotherapy
             in 28 days

          4. With a history of malignant tumor except uterine cervix cancer in situ or skin basal
             cell carcinoma

          5. Patients with medical conditions that indicate intolerant to adjuvant target therapy
             and related treatment, including severe infection, coagulation disorder, active peptic
             ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease

          6. Has symptomatic peripheral neuropathy &gt; grade 2 according to NCI

          7. Known severe allergy to any drugs in this study

          8. Has cardiac dysfunction or lung dysfunction defined as follows:

               -  grade ≥3 CHF according to NCI CTCAE v 5.0 or NYHA≥II

               -  angina which requires drug control, cardiac infraction, and any other vascular
                  disease with apparent clinical symptoms

               -  uncontrolled high-risk arrhythmia

               -  uncontrolled hypertension

          9. Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is
             known to be HIV positive

         10. Patient is pregnant or breast feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xuexin He, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Seaond Affiliated Hospital, Zhejiang University, School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xuexin He, MD</last_name>
    <phone>+86-18329139569</phone>
    <email>xuexinhe@zju.edu.cn</email>
  </overall_contact>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>November 7, 2019</last_update_submitted>
  <last_update_submitted_qc>November 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Second Affiliated Hospital, School of Medicine, Zhejiang University</investigator_affiliation>
    <investigator_full_name>xuexin he</investigator_full_name>
    <investigator_title>Associate chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

